Literature DB >> 25331073

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.

E Cecchin1, G Perrone2, S Nobili2, J Polesel3, E De Mattia1, C Zanusso1, P Petreni2, S Lonardi4, N Pella5, M D'Andrea6, D Errante7, F Rizzolio1, T Mazzei2, I Landini2, E Mini8, G Toffoli1.   

Abstract

Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treated with adjuvant FL with or without OXA, including a total of 262 cases. 5,10-Methylentetrahydrofolate reductase (MTHFR) MTHFR-1298 A>C (rs1801131) polymorphism had a concordant effect: MTHFR-rs1801131-1298CC genotype carriers had a worse disease free survival (DFS) in both the cohorts. In the pooled population MTHFR-rs1801131-1298CC carriers had also a worse overall survival. We computed a clinical score related to DFS including MTHFR-rs1801131, tumor stage, sex and tumor location, where rs1801131 is the most detrimental factor (hazard ratio=5.3, 95% confidence interval=2.2-12.9; P-value=0.0006). MTHFR-rs1801131 is a prognostic factor that could be used as an additional criteria for the choice of the proper adjuvant regimen in stage II/III colorectal cancer patients.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25331073     DOI： 10.1038/tpj.2014.64

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


  39 in total

1.  Letter to the editor: a meta-analyses of association between polymorphism of MTHFR A1298C and colorectal cancer risk.

Authors:  Hong Ge; Xiaoli Zheng; Erjiang Zhao; Xuewen Sheng; Su Lu; Siguo Cheng; Jinming Yu
Journal:  Int J Colorectal Dis       Date:  2012-02-21       Impact factor: 2.571

2.  Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.

Authors:  Marina Vignoli; Stefania Nobili; Cristina Napoli; Anna Laura Putignano; Maria Morganti; Laura Papi; Rosa Valanzano; Fabio Cianchi; Francesco Tonelli; Teresita Mazzei; Enrico Mini; Maurizio Genuardi
Journal:  Pharmacol Res       Date:  2011-04-23       Impact factor: 7.658

3.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Authors:  N M van der Put; F Gabreëls; E M Stevens; J A Smeitink; F J Trijbels; T K Eskes; L P van den Heuvel; H J Blom
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

Review 4.  Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells.

Authors:  Ying Huang; Wolfgang Sadée
Journal:  Cancer Lett       Date:  2005-10-05       Impact factor: 8.679

5.  Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy.

Authors:  Giuseppe Toffoli; Roberta Gafà; Antonio Russo; Giovanni Lanza; Riccardo Dolcetti; Franca Sartor; Massimo Libra; Alessandra Viel; Mauro Boiocchi
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

6.  Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.

Authors:  Kyung-Hun Lee; Hye Jung Chang; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Yung-Jue Bang; Sun Young Kim; Keun-Wook Lee; Jee Hyun Kim; Yong Sang Hong; Tae Won Kim; Young Suk Park; Won Ki Kang; Sang Joon Shin; Joong Bae Ahn; Gyeong Hoon Kang; Seung-Yong Jeong; Kyu Joo Park; Jae-Gahb Park; Tae-You Kim
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-13       Impact factor: 3.333

7.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

8.  The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.

Authors:  O Capitain; M Boisdron-Celle; A-L Poirier; S Abadie-Lacourtoisie; A Morel; E Gamelin
Journal:  Pharmacogenomics J       Date:  2007-08-14       Impact factor: 3.550

9.  Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.

Authors:  Ji-Youn Han; Hyeong-Seok Lim; Yong Hoon Park; Sung Young Lee; Jin Soo Lee
Journal:  Lung Cancer       Date:  2008-01-24       Impact factor: 5.705

10.  MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.

Authors:  S Afzal; S A Jensen; B Vainer; U Vogel; J P Matsen; J B Sørensen; P K Andersen; H E Poulsen
Journal:  Ann Oncol       Date:  2009-05-22       Impact factor: 32.976
View more
  10 in total

1.  Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.

Authors:  Rujiao Liu; Xiaoying Zhao; Xin Liu; Zhiyu Chen; Lixin Qiu; Ruixuan Geng; Weijian Guo; Guang He; Jiliang Yin; Jin Li; Xiaodong Zhu
Journal:  Tumour Biol       Date:  2015-08-28

2.  Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.

Authors:  Chih-Ching Yeh; Ching-Yu Lai; Shih-Ni Chang; Ling-Ling Hsieh; Reiping Tang; Fung-Chang Sung; Yi-Kuei Lin
Journal:  Int J Clin Oncol       Date:  2017-01-02       Impact factor: 3.402

3.  Associations of the MTHFR rs1801133 polymorphism with gastric cancer risk in the Chinese Han population.

Authors:  Zhiqiang Han; Huaming Sheng; Qiuzhi Gao; Yu Fan; Xiang Xie
Journal:  Biomed Rep       Date:  2020-11-17

Review 4.  The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines.

Authors:  Elena De Mattia; Rossana Roncato; Chiara Dalle Fratte; Fabrizio Ecca; Giuseppe Toffoli; Erika Cecchin
Journal:  Cancer Drug Resist       Date:  2019-03-19

Review 5.  Methylenetetrahydrofolate reductase polymorphisms and colorectal cancer prognosis: A meta-analysis.

Authors:  Xin-Lin Chen; Yu-Mei Wang; Fei Zhao; Zheng Chen; Xiaofei Yang; Cong Sun; Yunpeng Gao; Tian-Ge Yang; Guo Tian; Yi-Ming Chen; Shui-Lian Zhu; Xiao-Bing Lin; Feng-Bin Liu
Journal:  J Gene Med       Date:  2019-08-06       Impact factor: 4.565

Review 6.  Precision Medicine in Non Communicable Diseases.

Authors:  Mandana Hasanzad; Negar Sarhangi; Hamid Reza Aghaei Meybodi; Shekoufeh Nikfar; Fatemeh Khatami; Bagher Larijani
Journal:  Int J Mol Cell Med       Date:  2019-07-25

7.  HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Authors:  Marica Garziera; Ettore Bidoli; Erika Cecchin; Enrico Mini; Stefania Nobili; Sara Lonardi; Angela Buonadonna; Domenico Errante; Nicoletta Pella; Mario D'Andrea; Francesco De Marchi; Antonino De Paoli; Chiara Zanusso; Elena De Mattia; Renato Tassi; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

Review 8.  Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II.

Authors:  Matej Horvat; Uroš Potočnik; Katja Repnik; Rajko Kavalar; Borut Štabuc
Journal:  Gastroenterol Res Pract       Date:  2016-01-14       Impact factor: 2.260

Review 9.  SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.

Authors:  Raffaele Palmirotta; Claudia Carella; Erica Silvestris; Mauro Cives; Stefania Luigia Stucci; Marco Tucci; Domenica Lovero; Franco Silvestris
Journal:  Oncotarget       Date:  2018-05-18

10.  A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy.

Authors:  Elena De Mattia; Eva Dreussi; Marcella Montico; Sara Gagno; Chiara Zanusso; Luca Quartuccio; Salvatore De Vita; Michela Guardascione; Angela Buonadonna; Mario D'Andrea; Nicoletta Pella; Adolfo Favaretto; Enrico Mini; Stefania Nobili; Loredana Romanato; Erika Cecchin; Giuseppe Toffoli
Journal:  Front Pharmacol       Date:  2018-10-04       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.